Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 7/20 | 0.36 |
| ▸ | CTSL | P07711 | 6/20 | 0.36 |
| ▸ | CTSK | P43235 | 5/20 | 0.36 |
| ▸ | USP14 | P54578 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504228 | 0.88 | EPHX2 (0.39) | KDM4EALDH1A1POLBEGLN1USP14 | |
| SCHEMBL504103 | 0.86 | EPHX2 (0.41) | KDM4EALDH1A1POLBUSP14EPHX2 | |
| SCHEMBL503883 | 0.85 | EPHX2 (0.41) | KDM4EEGLN1USP14EPHX2PPARG | |
| SCHEMBL504299 | 0.84 | FFAR1 (0.46) | EPHX2LTA4HPPARGPPARA | |
| SCHEMBL334825 | 0.83 | USP14 (0.43) | KDM4EUSP14EPHX2PPARGPPARA | |
| SCHEMBL10076916 | 0.83 | PPARG (0.47) | KDM4EALDH1A1USP14EPHX2LTA4H | |
| SCHEMBL503817 | 0.81 | MEN1 (0.37) | KDM4EALDH1A1EGLN1CTSSCTSL | |
| SCHEMBL333611 | 0.81 | PPARG (0.47) | KDM4EALDH1A1USP14PPARGPPARA | |
| SCHEMBL333774 | 0.81 | PPARG (0.46) | PPARGPPARA | |
| SCHEMBL504356 | 0.81 | PPARG (0.42) | KDM4EUSP14PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | LTC4S, LTB4R2, LTB4R | KDM4E 1630/4885ALDH1A1 816/4885POLB 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.